Delcath Systems, Inc. (DCTH )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DCTH
- Company Delcath Systems, Inc.
- Price $15.11
- Changes Percentage -2.33
- Change -0.36
- Day Low $14.97
- Day High $16.38
- Year High $13.74
- Year Low $8.12
- Market Cap $404,421,095
- Price Avg 50 EMA (D) $11.95
- Price Avg 200 EMA (D) $10.45
- Exchange NASDAQ
- Volume 114,238
- Average Volume 484,257
- Open $15.67
- Previous Close $15.47
- EPS 0.01
- PE 1171.50
- Earnings Announcement 2026-08-05 04:00:00
- Shares Outstanding $34,521,647
Company brief: DELCATH SYSTEMS, INC. (DCTH )
- Healthcare
- Medical - Specialties
- Mr. Gerard J. Michel MBA, MS
- https://www.delcath.com
- US
- N/A
- 05-03-2018
- US24661P8077
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.